|
|
|
| Clinical study of Shenmai Injection combined with enteral nutrition in the treatment of hyperlipidemic severe acute pancreatitis |
| WANG Jian′gang1 WANG Yubo2 KONG Na1 |
1.Department of Gastroenterology, the Third People′s Hospital of Yunnan, Yunnan Province, Kunming 650011, China;
2.Department of Clinical Nutrition, the Third People′s Hospital of Yunnan, Yunnan Province, Kunming 650011, China |
|
|
|
Abstract Objective To investigate the efficacy and safety of Shenmai Injection combined with enteral nutrition in the treatment of hyper lipidemic severe acute pancreatitis (HLSAP). Methods Ninety-three patients with HLSAP admitted to the Third People′s Hospital of Yunnan from January 2016 to June 2018 were selected. According to the random number table method, the patients were divided into observation group (47 cases) and control group (46 cases). The control group was treated with enteral nutrition, the observation group was treated with Shenmai Injection combined with enteral nutrition. Both groups were treated continuously for 14 days. The clinical effect of the two groups was compared. The acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) and Balthazar CT score were evaluated and compared between the two groups before and after treatment. The levels of serum prealbumin (PAB), albumin (ALB), triacylglycerol (TG), C-reactive protein (CRP), immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) were detected and compared between the two groups before and after treatment. The occurrence of adverse reactions during the treatment was recorded. Results The total clinical effective rate of the observation group was 97.87% (46/47), which was significantly higher than 78.26% (36/46) of the control group, the difference was statistically significant (χ2 = 8.573, P = 0.003). After treatment, APACHEⅡ and Balthazar CT scores of the two groups were significantly lower than those before treatment (P ＜ 0.05), which of the observation group were lower than the control group (P ＜ 0.05). After treatment, the serum levels of PAB, ALB, IgA, IgM and IgG in the two groups were significantly higher than those before treatment (P ＜ 0.05), the serum levels of TG and CRP were significantly lower than those before treatment (P ＜ 0.05), and the improvement of serum levels of PAB, ALB, TG, CRP, IgA, IgM and IgG in the observation group was significantly better than those in the control group (P ＜ 0.05). No serious adverse reactions were found during the treatment in both groups. Conclusion Shenmai Injection combined with enteral nutrition in the treatment of HLSAP has significant clinical efficacy, which can significantly improve the nutritional status, reduce inflammatory reaction, enhance immune function, and has good security.
|
|
|
|
|
|
[1] 杨学华.乌司他丁与连续性血液净化联合治疗重症急性胰腺炎的临床疗效[J].实用医技杂志，2017，24（1）：88-89，90.
[2] 张奕秉，潘杰，朱丽明，等.高脂血症性急性胰腺炎的临床特点和预后分析[J].重庆医学，2013，11（33）：4030-4031，4033.
[3] 杨明，王春友.《急性胰腺炎诊治指南（2014）》解读[J].浙江医学，2015，37（11）：909-911.
[4] 林介军，周建伟，朱方超，等.血液净化联合早期强化肠内营养支持治疗高脂血症性急性胰腺炎的疗效分析[J].浙江医学，2017，39（24）：2290-2292.
[5] 赵洪涛，张占云，李威，等.乌司他丁联合参麦注射液治疗急性重症胰腺炎疗效观察[J].中华普外科手术学杂志电子版，2015，9（4）：259-261.
[6] 中华医学会消化病学分会胰腺疾病学组，《中华胰腺病杂志》编辑委员会，《中华消化杂志》编辑委员会，等.中国急性胰腺炎诊治指南（2013，上海）[J].中华胰腺病杂志，2013，13（2）：73-78.
[7] 刘洁，任佳，郭树彬.《2013年急性胰腺炎临床实践指南》回顾与解读[J].临床误诊误治，2015，28（4）：84-87.
[8] Papachristou GI，Muddana V，Yadav D，et al. Comparison of BISAP，Ransons，APACHE Ⅱ，and CTSI scores in predicting organ failure，complications，and mortality in acute pancreatitis [J]. Am J Gastroenteral，2009，105（2）：435-441.
[9] Balthazar EJ. Acute pancreatitis：assessment of severity with clinical and CT evaluation [J]. Radiology，2002，223（3）：603-613.
[10] 杨立新，杜丽川，刘欣，等.四种评分标准对高脂血症性急性胰腺炎病情和预后的评估作用[J].中华内科杂志，2016，55（9）：695-699.
[11] 吕厦，曹志蔚，唐芳，等.生大黄水浸液灌胃与芒硝外敷结合西医常规疗法治疗重症急性胰腺炎[J].国际中医中药杂志，2018，40（10）：922-925.
[12] Kota SK，Krishna SV，Lakhtakia S，et al. Metabolic pancreatitis：etiopathogenesis and management [J]. Indian J Endocrinol Metab，2013，17（5）：799-805.
[13] 刘博，王玉梅，孔维，等.早期免疫型肠内营养联合活菌制剂对高脂血症性急性胰腺炎患者临床预后的影响[J].现代仪器与医疗，2018，24（3）：86-88.
[14] 黄学勤，张璋，曹火留，等.微生态肠内营养支持治疗重症急性胰腺炎的疗效[J].实用临床医学，2016，17（11）：12-14，20.
[15] 杜伟.疏血通注射液辅助治疗高脂血症性急性胰腺炎45例疗效观察[J].山东医药，2014，54（6）：57-58.
[16] 余健，辛艳飞，宣尧仙.参麦注射液药理作用的物质基础研究进展[J].医药导报，2013，32（4）：497-500.
[17] 和芳，张玫，吴晓光，等.甲磺酸加贝酯对非胆源性急性胰腺炎全身炎症反应综合征转归的影响[J].中国医院用药评价与分析，2017，17（10）：1330-1333.
[18] 陆贝，于源泉，殷俊杰，等.过氧化物酶体增殖物激活受体-γ激动剂对急性胰腺炎大鼠肺损伤的保护机制研究[J].中国现代医生，2017，55（18）：38-41，封3.
[19] 周健.参麦注射液联合免疫增强型肠内营养治疗高脂血症性急性胰腺炎的疗效分析[J].检验医学与临床，2018，15（15）：2262-2265.
[20] 贾鹏冲，薛飞，付强，等.早期肠内营养治疗高脂血症性重症急性胰腺炎的安全性及疗效观察[J].中华实用诊断与治疗杂志，2018，32（10）：1022-1024.
[21] 陈立新，阮素莲，吴江山，等.血液灌流联合血液透析滤过对高脂血症胰腺炎伴急性肾损伤的疗效研究[J].中国医药科学，2017，7（17）：236-238.
[22] 李渊，郭进，房伟，等.早期通里攻下联合肠内营养治疗重症急性胰腺炎40例[J].西部中医药，2017，30（4）：110-112.
[23] 单伟峰，李艳丽，杨元生.参麦注射液联合生长抑素治疗急性胰腺炎患者的临床研究[J].医学综述，2013，19（2）：383-384.
[24] 张晓勤，雷雨，罗晓秀，等.血液灌流联合柴芍承气汤治疗高脂血症性胰腺炎的临床观察[J].中国现代医生，2017，55（4）：101-103，106.
[25] 张飞虎，孔立，董晓斌，等.参麦注射液对重症急性胰腺炎大鼠多器官保护作用的实验研究[J].中国中西医结合急救杂志，2016，23（3）：257-260. |
|
|
|
